Articles
Patients & Caregivers

The Sickle Cell Awareness Group of Ontario (SCAGO) is pleased with the news of CASGEVY (Exagamglogene Autotemcel) receiving marketing authorization for the treatment of Sickle Cell and Thalassemia disorders in Canada.

Pfizer Inc. announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved.

Improving the knowledge of peers and families about blood transfusion in sickle cell disease

The Role of Parents & Family Members in sickle cell disease pain management

Improving care and treatment by utilising informed decision making based on pateint preferences and best practices.

Understanding how COVID-19 affects your child with sickle cell disease.

A race adjustment in kidney disease fuction equations to provide unbiased clinical management in Canada

Organizational toolkit to engage community members about clinical trials.

The ins and outs of Hydroxyurea, a popular treatment option for individuals with sickle cell disease.

Understanding iron overload from blood transfusions, the risks and complicaitons.

Summary poster of current scientific evidence about appropriate medical opioid use to manage pain for children and youth living with Sickle Cell Disease.